Kurt Andreason, MD
Ophthalmology · Bend, ORNPI 1013990027
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,072 of the $12,708 with a category attached, or 71.4%. 25 manufacturers reported payments, led by Biotissue Holdings Inc. at 37.9% of the total. Among ophthalmology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $77.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$5K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$1K
- Rxsight Inc$994
- AbbVie$587
- Glaukos Corporation$524
- plus $2K from 19 others
What the payments were for
- Travel & lodging$3,63629%
- Food & beverage$9,07271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 33 | $4,819 |
| Johnson & Johnson Surgical Vision, Inc. | 26 | $2,490 |
| Alcon | 19 | $1,168 |
| Rxsight Inc | 17 | $994 |
| AbbVie(2 entities) | 16 | $587 |
| Glaukos Corporation | 8 | $524 |
| Microsurgical Technology, Inc. | 2 | $381 |
| Mallinckrodt Hospital Products Inc. | 6 | $274 |
| Aerie Pharmaceuticals, Inc. | 2 | $240 |
| Bausch & Lomb Americas Inc. | 4 | $225 |
| Novartis | 5 | $166 |
| Tarsus Pharmaceuticals, Inc. | 1 | $133 |
| Mallinckrodt Enterprises LLC | 1 | $119 |
| Kala Pharmaceuticals, Inc. | 4 | $119 |
| Amgen | 6 | $101 |
| Rayner Intraocular Lenses Limited | 1 | $88 |
| Genentech USA, Inc. | 3 | $68 |
| Vantage Technology LLC | 2 | $37 |
| Acclarent, Inc | 1 | $36 |
| Thea Pharma Inc. | 2 | $34 |
| Dompe US, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$2,701
- AmnioGraft$2,230
- Tecnis 1-piece IOL$1,362
- Tecnis 3-piece IOL$1,362
- Tecnis Symphony IOL$1,362
- Tecnis Symphony Toric IOL$1,362
- AmnioGuard$556
- RXSIGHT CONTACT LENS$253
- RXSIGHT INJECTOR CARTRIDGE$253
- RXSIGHT INJECTOR HANDPIECE$253
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$253
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$253
- Rhopressa$240
- Rocklatan$240
- One Series Ultra IOL Delivery System$233
- DURYSTA$149
- ACTIVEFOCUS$143
- XDEMVY$133
- Tecnis Simplicity$133
- PanOptix$131
How this compares
$12,708 in reported general payments places this provider in the 95th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $8,823 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 309 | $5,876 |
| Latanoprost | 292 | $5,492 |
| Fluorometholone | 29 | $2,545 |
| Prednisolone Acetate | 48 | $1,852 |
| Brimonidine Tartrate | 13 | $1,049 |
| Doxycycline Hyclate | 17 | $645 |
| Timolol Maleate | 34 | $511 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $397 |
| ValacyclovirValacyclovir Hcl | 12 | $339 |
| Dorzolamide Hcl | 18 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $587 | $8,82312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in Bend
- Brian DesmondBend$10K
- Thomas FitzsimmonsBend$4K
- Patricia BuehlerBend$3K
- Meryl SundyBend$3K
- David HuangCorvallis$67K
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Bart AdamsPendleton$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.